One-Year Outcomes of a Digital Twin Intervention for Type 2 Diabetes: A Retrospective Real-World Study
Authors:
Preprint
- 3 July 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
This retrospective observational study, building on prior research that demonstrated the efficacy of the Digital Twin (DT) Precision Treatment Program over shorter follow-up periods, aimed to examine glycemic control and reduced anti-diabetic medication use after one year in a DT commercial program. T2D patients enrolled had adequate hepatic and renal function and no recent cardiovascular events. DT intervention powered by artificial intelligence utilises precision nutrition, activity, sleep, and deep breathing exercises. Outcome measures included HbA1c change, medication reduction, anthropometrics, insulin markers, and CGM metrics. Of 1985 enrollees, 132 (6.6%) were lost to follow-up, leaving 1853 participants who completed one year. At one year, participants exhibited significant reductions in HbA1c [mean change (SD) -1.8 (1.7)%, p<0.0001], with 1650 (89.0%) achieving HbA1c levels below 7%. At baseline, participants were taking mean anti-diabetic medications of 1.9 (1.4) which decreased to 0.5 (0.7) after one year [change: -1.5 (1.3), p<0.0001]. There were also significant decreases in weight [-4.8 (6.0) kg, p<0.0001], improvements in insulin resistance as measured by HOMA2-IR [-0.1 (1.2), p=0.00005], and enhancements in β-cell function [HOMA2-B; +21.6 (47.7); p<0.0001], along with better CGM metrics. These findings suggest that DT intervention could play a vital role in the future of T2D care.Keywords
All Related Versions
- Version 1, 2024-07-03, Research Square
- Published version: Scientific Reports, 14 (1), 1.
This publication has 28 references indexed in Scilit:
- Digital Twin-Enabled Personalized Nutrition Improves Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes: Results of a 1-Year Randomized Controlled StudyEndocrine Practice, 2023
- Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trialTranslational Research, 2021
- Retrospective study of glycemic variability, BMI, and blood pressure in diabetes patients in the Digital Twin Precision Treatment ProgramScientific Reports, 2021
- Time-in-range as a target in type 2 diabetes: An urgent needHeliyon, 2021
- Human postprandial responses to food and potential for precision nutritionNature Medicine, 2020
- Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individualsThe American Journal of Clinical Nutrition, 2019
- Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled StudyDiabetes Therapy, 2018
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trialThe Lancet, 2018
- Major rapid weight loss induces changes in cardiac repolarizationJournal of Electrocardiology, 2016
- Personalized Nutrition by Prediction of Glycemic ResponsesCell, 2015